20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
OmniAb Inc. (OABI) operates in the BIOTECHNOLOGY industry and is headquartered in EmeryVille, United States with about 89 employees. Its market capitalization is roughly $751 million. In the fiscal year ended 2025-12-31, OABI reported $19M in revenue and ($65M) in net income.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.
Interactive charts & full statements → Open the OABI valuation workbench →
| Income statement | TTM → 2026-09-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $39M | $19M | $26M | $34M | $59M | $35M | $23M | $18M |
| Gross Profit | $26M | ($3M) | $26M | $34M | $59M | $35M | $23M | $18M |
| Gross Margin % | 66.7% | -18.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($47M) | ($72M) | ($75M) | ($69M) | ($27M) | ($36M) | ($26M) | ($13M) |
| Operating Margin % | -120.5% | -383.2% | -282.3% | -203.2% | -45.1% | -102.5% | -110.1% | -71.1% |
| Net Income | ($44M) | ($65M) | ($62M) | ($51M) | ($22M) | ($27M) | ($18M) | ($14M) |
| Net Margin % | -112.8% | -347.0% | -235.0% | -148.2% | -37.8% | -77.8% | -75.5% | -74.2% |
| EBITDA | — | ($45M) | ($48M) | ($45M) | ($8M) | ($18M) | ($11M) | ($3M) |
| Earnings Per Share (EPS) | $-0.34 | $-0.57 | $-0.61 | $-0.51 | $-0.26 | $-0.24 | $-0.15 | $-0.12 |
| Shares Outstanding (M) | — | 114M | 102M | 100M | 85M | 115M | 115M | 115M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $4M | $13M | $14M | $8M | $2M | $4M | $4M | $11M | $4M |
| Gross Profit | $4M | $13M | $8M | $1M | ($2M) | $4M | $4M | $11M | $4M |
| Gross Margin % | 100.0% | 95.5% | 58.3% | 7.9% | -109.2% | 93.3% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($16M) | ($7M) | ($8M) | ($16M) | ($18M) | ($16M) | ($19M) | ($16M) | ($20M) |
| Operating Margin % | -400.0% | -49.5% | -54.9% | -186.8% | -811.3% | -416.2% | -453.6% | -147.0% | -473.7% |
| Net Income | ($16M) | ($6M) | ($8M) | ($14M) | ($17M) | ($16M) | ($18M) | ($13M) | ($16M) |
| Net Margin % | -400.0% | -43.7% | -53.5% | -169.3% | -738.0% | -407.4% | -438.1% | -121.0% | -392.4% |
| EBITDA | — | ($6M) | ($2M) | ($7M) | ($11M) | ($15M) | ($14M) | ($8M) | ($14M) |
| Earnings Per Share (EPS) | $-0.12 | $-0.05 | $-0.06 | $-0.11 | $-0.14 | $-0.15 | $-0.17 | $-0.12 | $-0.16 |
| Shares Outstanding (M) | — | 129M | 128M | 128M | 115M | 106M | 106M | 105M | 102M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-09-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $3M | ($36M) | ($40M) | $2M | ($4M) | ($6M) | $4M | ($5M) |
| Capital Expenditures (CapEx) | — | $1M | $2M | $2M | $17M | $4M | $2M | $0M |
| Free Cash Flow (FCF) | $3M | ($37M) | ($42M) | $1M | ($21M) | ($10M) | $2M | ($5M) |
| FCF Margin % | 7.7% | -198.3% | -157.4% | 2.1% | -35.1% | -28.0% | 8.0% | -29.8% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $11M | $3M | ($5M) | ($6M) | ($10M) | ($5M) | ($16M) | ($4M) | ($7M) |
| Capital Expenditures (CapEx) | — | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | $11M | $3M | ($5M) | ($6M) | ($10M) | ($5M) | ($16M) | ($4M) | ($7M) |
| FCF Margin % | 275.0% | 19.1% | -35.3% | -67.8% | -444.2% | -136.3% | -387.1% | -36.3% | -161.3% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-09-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $291M | $301M | $326M | $375M | $421M | $304M | $295M | $262M |
| Cash & Cash Equivalents | $23M | $26M | $28M | $16M | $33M | ($14M) | ($3M) | — |
| Total Liabilities | $42M | $34M | $38M | $61M | $80M | $70M | $60M | $44M |
| Total Debt (Short + Long-Term) | — | $4M | $4M | $3M | $2M | $1M | $1M | $0M |
| Total Shareholders' Equity | $249M | $267M | $288M | $315M | $341M | $234M | $236M | $218M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive OABI viewer.
About TickerBase · Data methodology & sources · Privacy · Terms